Dr Praveena Kumara


Nucleic acid testing (NAT) is a molecular technique for screening blood donations to reduce the risk of transfusion transmitted infections (TTIs) in the recipients, thus providing an additional layer of blood safety. It was introduced in the developed countries in the late 1990s and early 2000s and presently around 33 countries in the world have implemented NAT for human immunodeficiency virus (HIV) and around 27 countries for hepatitis B virus (HBV). NAT technique is highly sensitive and specific for viral nucleic acids. It is based on amplification of targeted regions of viral ribonucleic acid or deoxyribonucleic acid (DNA) and detects them earlier than the other screening methods thus, narrowing the window period of HIV, HBV and hepatitis C virus (HCV) infections. NAT also adds the benefit of resolving false reactive donations on serological methods which is very important for donor notification and counseling. This study is one such effort to find the best way to diagnose


Nucleic acid testing, Transfusion transmitted infections, Blood transfusion

Full Text:



Jasani J, Patel V, Bhuva K, Vaihhani A, Patel H. Seroprevalence of transfusion transmissible infections among blood donors in a tertiary care hospital. Int J Biol Med Res. 2012;31:1423-5.

Bihl F, Castelli D, Marincola F, Dodd RY, Brander C. Transfusion-transmitted infections. Journal of translational medicine. 2007;5(1):25.

Standards For Blood Banks & Blood Transfusion Services, [1] National AIDS Control Organization, Ministry of Health and Family Welfare, Government of India, New Delhi 2007. .

ShrivaSTava M, MiShra S. Nucleic Acid Amplification Testing (NAT): An Innovative Diagnostic Approach for Enhancing Blood Safety.

Hans R, Marwaha N. Nucleic acid testing-benefits and constraints. Asian journal of transfusion science. 2014;8(1):2.

Makroo R, Choudhury N, Jagannathan L, Parihar-Malhotra M, Raina V, Chaudhary R, et al. Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus-1 & hepatitis B & C viruses in Indian blood donors. Indian Journal of Medical Research. 2008;127(2):140.

O'brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion‐transmitted infections in donations made to Canadian Blood Services. Transfusion. 2007;47(2):316-25.

Giri PA, Deshpande JD, Phalke DB, Karle LB. Seroprevalence of transfusion transmissible infections among voluntary blood donors at a tertiary care teaching hospital in rural area of India. Journal of family medicine and primary care. 2012;1(1):48.

Chandrasekaran S, Palaniappan N, Krishnan V, Mohan G, Chandrasekaran N. Relative prevalence of hepatitis B viral markers and hepatitis C virus antibodies (anti HCV) in Madurai, south India. Indian journal of medical sciences. 2000;54(7):270-3.

Jain R, Aggarwal P, Gupta GN. Need for nucleic acid testing in countries with high prevalence of transfusion-transmitted infections. ISRN hematology. 2012;2012.


  • There are currently no refbacks.